Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2606-2611

  Govender, Nelesh P ^a,b   Patel, Jaymati ^a   Van Wyk, Marelize ^a   Chiller, Tom M ^c   Lockhart, Shawn R ^c  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SOUTH AFRICA;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SOUTH AFRICA; TIME FACTORS;

EID: 79956335301     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00048-11     Document Type: Article

References (41)

1. Aller, A. I., et al. 2005. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005. Chemotherapy 53:300-305.
2. Aller, A. I., et al. 2000. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob. Agents Chemother. 44:1544-1548.
3. Apisarnthanarak, A., and L. M. Mundy. 2008. The impact of primary prophylaxis for cryptococcosis on fluconazole resistance in Candida species. J. Acquir. Immune Defic. Syndr. 47:644-645.
4. Berg, J., C. J. Clancy, and M. H. Nguyen. 1998. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin. Infect. Dis. 26:186-187.
5. Bicanic, T., et al. 2009. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 23:701-706.
6. Bicanic, T., T. Harrison, A. Niepieklo, N. Dyakopu, and G. Meintjes. 2006. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin. Infect. Dis. 43:1069-1073.
7. Bicanic, T., et al. 2009. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J. Acquir. Immune Defic. Syndr. 51:130-134.
8. Bicanic, T., et al. 2005. Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. Lancet Infect. Dis. 5:530-531.
9. Brandt, M. E., et al. 2005. Serotype and susceptibility testing of Cryptococcus neoformans isolates: population-based surveillance, Gauteng Province (Johannesburg), South Africa, 2002-04, abstr. F-004. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Brandt, M. E., et al. 2001. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob. Agents Chemother. 45:3065-3069.
11. Chandenier, J., et al. 2004. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur. J. Clin. Microbiol. Infect. Dis. 23:506-508.
12. Clinical and Laboratory Standards Institute. 2008. M27-S3. Reference method for broth dilution antifungal susceptibility testing of yeasts; 3rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Clinical and Laboratory Standards Institute. 2008. M27-A3 Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Collett, G., and A. Parrish. 2007. Fluconazole donation and outcomes assessment in cryptococcal meningitis. S. Afr. Med. J. 97:175-176.
15. Dannaoui, E., et al. 2006. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob. Agents Chemother. 50:2464-2470.
16. Desnos-Ollivier, M., et al. 2010. Mixed infections and in vivo evolution in the human fungal pathogen Cryptococcus neoformans. mBio 1:e00091-10.
17. Dias, A. L., et al. 2006. Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates. J. Med. Microbiol. 55:1693-1699. (Pubitemid 44902033)
18. Garcia-Hermoso, D., G. Janbon, and F. Dromer. 1999. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37:3204-3209.
19. Govender, N., et al. 2010. Trends in treatment of adults with incident cryptococcosis, South Africa, 2005-2008, abstr. P-800. Abstr. 17th Conf. Retrovir. Opp. Infect.
20. Govender, N., et al. 2006. GERMS-SA: a national South African surveillance network for bacterial and fungal diseases. Communicable Diseases Surveillance Bulletin. National Institute for Communicable Diseases, Johannesburg, South Africa. http://www.nicd.ac.za.
21. Jarvis, J. N., et al. 2009. Screening for cryptococcal antigenaemia in patients accessing an antiretroviral treatment program in South Africa. Clin. Infect. Dis. 48:856-862.
22. Jarvis, J. N., G. Meintjes, and T. S. Harrison. 2010. Outcomes of cryptococcal meningitis in antiretroviral naive and experienced patients in South Africa. J. Infect. 60:496-498.
23. Jarvis, J. N., et al. 2010. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect. Dis. 10:67.
24. Jarvis, J. N., G. Meintjes, Z. Williams, K. Rebe, and T. S. Harrison. 2010. Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. S. Afr. Med. J. 100: 378-382.
25. Jessup, C. J., et al. 1998. Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients. J. Clin. Microbiol. 36:2874-2876.
26. Kambugu, A., et al. 2008. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin. Infect. Dis. 46:1694-1701.
27. Lortholary, O., et al. 2006. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20:2183-2191. (Pubitemid 44684709)
28. Lozano-Chiu, M., V. L. Paetznick, M. A. Ghannoum, and J. H. Rex. 1998. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J. Clin. Microbiol. 36:2817-2822.
29. Manosuthi, W., et al. 2006. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis. J. Med. Assoc. Thai. 89:795-802.
30. Maxwell, M. J., S. A. Messer, R. J. Hollis, D. J. Diekema, and M. A. Pfaller. 2003. Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans. J. Clin. Microbiol. 41:97-99.
31. McCarthy, K. M., et al. 2006. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 20:2199-2206. (Pubitemid 44684711)
32. Mitchell, T. G., and J. R. Perfect. 1995. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
33. Perfect, J. R., et al. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322.
34. Petrou, M. A., and D. C. Shanson. 2000. Susceptibility of Cryptococcus neoformans by the NCCLS microdilution and Etest methods using five defined media. J. Antimicrob. Chemother. 46:815-818.
35. Pfaller, M. A., et al. 2005. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43:2163-2167.
36. Pfaller, M. A., et al. 1999. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob. Agents Chemother. 43:169-171.
37. Pfaller, M., et al. 1998. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients. Diagn. Microbiol. Infect. Dis. 32:191-199.
38. Sar, B., et al. 2004. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J. Antimicrob. Chemother. 54:563-565.
39. South African Department of Health. 2000. Recommendations for the prevention and treatment of opportunistic and HIV-related diseases in adults - 2000. South African Department of Health, Pretoria, South Africa. http://www.doh.gov.za/aids/. Accessed 31 May 2010.
40. Warnock, D. W., E. M. Johnson, and T. R. Rogers. 1998. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy. J. Antimicrob. Chemother. 42:321-331.
41. Wertheimer, A. I., T. M. Santella, and H. J. Lauver. 2004. Successful public/private donation programs: a review of the Diflucan Partnership Program in South Africa. J. Int. Assoc. Physicians AIDS Care (Chic.). 3:74-75.